Fly News Breaks for February 15, 2017
Feb 15, 2017 | 07:09 EDT
H.C. Wainwright analyst Ed Arce downgraded Aviragen Therapeutics to Neutral after the company's lead drug candidate, vapendavir, missed its primary and several secondary endpoints in a Phase 2b trial. The analyst sees a lack of visibility and catalysts.
News For AVIR From the Last 2 Days
There are no results for your query AVIR